The group’s principle activity is to provide stem cell engineering services dedicated to creating, delivering, and commercializing cell and drug therapies to treat chronic diseases including diabetes. The group operates from United States.
Executive Information
Name
Title
Email
Alan Lewis
Dir., CEO, Pres.
N/A
Fred Middleton
Chmn., MD
N/A
Allan Robins
CTO, VP
N/A
Anne Sandan
Controller, Sr. Dir. - Corporate Administration, Corp. Sec.
